Next CRSG meeting: 📅Fri 17 Apr 2026, 🚩London. Details 👇 🔗 prostatecanceruk.org/research/for...

🧵[5/6] 💡 Got a new trial idea to improve outcomes for men with prostate cancer? Use our form and submit your proposal Deadline: 4pm, Fri 13 Feb Applicants are encouraged to present their ideas and take part in the discussion at the next CRSG meeting. prostatecanceruk.org/research/for...

🧵[4/6] 🌱 Early-career clinical researchers — your opportunity is here! Apply for one of two CRSG observer roles to learn from leaders, connect nationally & grow your research career in prostate cancer. Deadline: 4pm, Fri 16 Jan

🧵[3/6] 👥 We’re recruiting Full Members! Expertise wanted in: 🧬 Pathology 🏥 Primary care 💉 Research nursing 🩻 Radiology Join us in shaping UK prostate cancer clinical research. Deadline: 4pm, Fri 16 Jan

🧵[2/6] The CRSG will shape clinical prostate cancer research by: 🔍 Identifying key research gaps 💪 Strengthening study design early 👏 Encouraging collaboration 🧑‍🎓 Mentoring early-career researchers

🧵[1/6] 📣 Big news for clinical prostate cancer researchers! The NCRI Prostate Group has re-established as UK Prostate Cancer Clinical Research Strategy Group (CRSG) - a national hub for collaboration & innovation in prostate cancer research. Learn more 👇 prostatecanceruk.org/research/for...

As debate grows over targeted #ProstateCancer screening, experts call for careful evaluation. "We can often find disease that doesn't need to be treated and we end up causing harm" — Prof Hashim Ahmed (@londonprostate1.bsky.social) @imperialsandc.bsky.social www.bbc.co.uk/news/article...

Rishi Sunak: Prostate cancer screening could 'save countless lives'

The former PM is among those in favour of targeted screening for men most at risk, but some medical experts are sceptical.

bbc.co.uk

Update of #IP7PACIFIC presented by @ajwlight.bsky.social at #AUA25 🇺🇸 This will be the first trial to provide definitive evidence comparing bpMRI vs mpMRI, alongside fusion vs cognitive biopsy >1200 patients recruited across the UK - watch this space

Update of #IP9ATLAS presented by Archana Gopalakrishnan at #AUA25 🇺🇸 This pivotal RCT will evaluate MRI-based surveillance for patients with GG1-2 cancer starting active surveillance Recruitment is open across the UK!

That’s a wrap on #AUA25 for Team IP! See you in Washington DC for #AUA26! 🇺🇸

New publication alert! 🚨 A clinician survey on the current practices within the prostate cancer diagnostic pathway in the United Kingdom - Uma Walters et al (Journal of Clinical Urology) 🔗 doi.org/10.1177/2051...

5yr outcomes following Rezum for >80mL prostates presented by @ajwlight.bsky.social (on behalf of Yan Leung) #AUA25 🇺🇸 Take home message - 3 of 4 patients were free of retreatment by 5 years

Excellent podium presentation by our resident Chase Ng on >1200 patients in #RAPID discharged with negative MRI or biopsy Only 1 in 12 developed csPCa & 1 in 20 needed cancer treatment by 5 years More evidence of the oncological efficacy of pre-biopsy MRI! #AUA25 🇺🇸

@ajwlight.bsky.social presents preliminary validation data on the #TARGET scoring system - good specificity and NPV for detecting GG2+ in-field disease Watch this space for our definitive multi centre validation study! #AUA25 🇺🇸

Building on our #IP8FLUORESCE study is #IB1LaserCOMPLETE - using ex vivo fluoresce confocal microscopy to establish muscle status in TURBT, presented by Archana Gopalakrishnan Recruitment is under way - watch this space for results soon! #AUA25 🇺🇸

In further #RAPID data, Chase Ng shows that patients discharged from a pre-biopsy MRI pathway with ASAP or HGPIN do not have a greater risk of subsequent csPCa or treatment than patients discharged without #AUA25 🇺🇸

Powerful messages from @londonprostate1.bsky.social in the focal therapy plenary crossfire debate Most intermediate risk cases are suitable, focal therapy is very effective, and the functional outcomes are superior. Surgeon training is crucial! #AUA25 🇺🇸

Pilot results from #IP2ATLANTA on novel cytoreductive treatments to the prostate & mets in de novo mHSPC presented by @londonprostate1.bsky.social #AUA25 🇺🇸 Take home - these treatments are safe and justified Recruitment for the main trial has completed - PFS endpoint to be reported 2027

📢 Join us at @IP_London We are recruiting a Clinical Research Fellow to join the #IP13AVIDITY team: RCT evaluating the role of PSMA PET/CT in directing treatment in patients w/ high-risk PCa (closing 15/04) 🔗 www.imperial.ac.uk/jobs/search-... @londonprostate1.bsky.social @connorurol.bsky.social

Description

Please note that job descriptions are not exhaustive, and you may be asked to take on additional duties that align with the key responsibilities ment...

imperial.ac.uk

💬 #TRANSFORM will look at new ways of screening to reduce false positives, reduce biopsy rates and reduce diagnosing low risk cancers whilst finding more high risk cancers that need treating. @londonprostate1.bsky.social @prostatecanceruk.bsky.social @nihr.bsky.social www.lbc.co.uk/opinion/view...

I treat prostate cancer every day – now I'm launching a study that could transform screening and save lives

The debate on screening for prostate cancer has been raging for over two decades.

lbc.co.uk

Great to see Professor Hashim Ahmed @londonprostate1.bsky.social talking @nickferrarilbc.bsky.social through his PSA blood test this morning, and sharing why the TRANSFORM trial is vital for finding the best way to screen men for #ProstateCancer. prostatecanceruk.org/research/tra...

Imperial Prostate@ip-london.bsky.social · last yr.

💬 #TRANSFORM will look at new ways of screening to reduce false positives, reduce biopsy rates and reduce diagnosing low risk cancers whilst finding more high risk cancers that need treating. @londonprostate1.bsky.social @prostatecanceruk.bsky.social @nihr.bsky.social www.lbc.co.uk/opinion/view...

Two weeks to go! Imperial Prostate Masterclass In association with Focal Therapy Society @ip-london.bsky.social www.imperialprostatemasterclass.org

With presentations from 4 IP trials and multiple other projects, it’s been a fantastic #EAU25 for Imperial Prostate 🇪🇸 See you next year in London for #EAU26! 🇬🇧

#IP2ATLANTA RCT pilot result #EAU25 🇪🇸 🔬 9 in 10 patients have a viable prostate tumour despite ADT+ARTA/Doce 🚦Early signal in prostate cancer mortality for cytoreductive arms 📈 Surgery, radiotherapy or ablation + SABR safe - Recruited (n=433) PFS exp.2027! @connorurol.bsky.social

It’s a big last day at #EAU25 for our team! 🇪🇸 @connorurol.bsky.social - 2x #IP2ATLANTA pilot study results (12:00) Mr Chase Ng - #RAPID 5-yr follow-up for negative biopsy patients (12:05) Mr Nikhil Mayor - #IP8FLUORESCE late breaking results (12:15)

Mr Chase Ng presents 5-year follow-up data for patients discharged with negative MRI/biopsy from our #RAPID pathway #EAU25 🇪🇸 1 in 12 were subsequently diagnosed with GG2+ cancer and 1 in 20 needed treatment - this further highlights the efficacy of MRI-based diagnostics!

Building on this morning’s #NeuroSAFE data, @nikhilmayor.bsky.social presents late-breaking results from #IP8FLUORESCE, assessing the diagnostic accuracy of FCM for detecting positive margins intra-op Feasible, quick and good sensitivity and specificity for detecting margins ≥3mm! #EAU25 🇪🇸

Nice work by Deepika! #EAU2025 #EAU25

Imperial Prostate@ip-london.bsky.social · last yr.

Lastly for Imperial Prostate today @ #EAU25 🇪🇸 is Ms Deepika Reddy in the new technologies & focal therapy in localised PCa session Traditional risk classification strategies developed for radical treatment are not transferrable to focal therapy outcomes. Risk models are in development!

Lastly for Imperial Prostate today @ #EAU25 🇪🇸 is Ms Deepika Reddy in the new technologies & focal therapy in localised PCa session Traditional risk classification strategies developed for radical treatment are not transferrable to focal therapy outcomes. Risk models are in development!

Well done Yan! #eau25 #eau2025 Rezum a good option for men with slightly larger glands

Imperial Prostate@ip-london.bsky.social · last yr.

Excellent presentation by Miss Yan Leung on 5-year outcomes after Rezum in >80mL prostates #EAU25 🇪🇸 75% retreatment-free at 5 years and the majority satisfied with their treatment!